CR20140142A - Variantes delfactor 21 del crecimiento de fibroblastos - Google Patents

Variantes delfactor 21 del crecimiento de fibroblastos

Info

Publication number
CR20140142A
CR20140142A CR20140142A CR20140142A CR20140142A CR 20140142 A CR20140142 A CR 20140142A CR 20140142 A CR20140142 A CR 20140142A CR 20140142 A CR20140142 A CR 20140142A CR 20140142 A CR20140142 A CR 20140142A
Authority
CR
Costa Rica
Prior art keywords
variants
fibroblast growth
fgf21
dyslipidemia
obesity
Prior art date
Application number
CR20140142A
Other languages
English (en)
Inventor
Craig Duane Dickinson
David Albert Driver
Ryan James Darling
Malgorzata Donata Gonciarz
Radmila Micanovic
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46964112&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CR20140142(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of CR20140142A publication Critical patent/CR20140142A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/50—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1825—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Obesity (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La presente invención se refiere a variantes estables y/o farmacológicamente potentes del factor 21 de crecimiento del fibroblasto humano (FGF21), composiciones farmacéuticas que comprenden variantes del FGF21, y métodos para tratar diabetes tipo 2, obesidad, dislipidemia, o síndrome metabólico, o cualquier combinación de los mismos, usando tales variantes.
CR20140142A 2011-10-04 2014-03-27 Variantes delfactor 21 del crecimiento de fibroblastos CR20140142A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201161542906P 2011-10-04 2011-10-04

Publications (1)

Publication Number Publication Date
CR20140142A true CR20140142A (es) 2014-05-02

Family

ID=46964112

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20140142A CR20140142A (es) 2011-10-04 2014-03-27 Variantes delfactor 21 del crecimiento de fibroblastos

Country Status (27)

Country Link
US (2) US8541369B2 (es)
EP (1) EP2763689B1 (es)
JP (1) JP6060167B2 (es)
KR (1) KR20140059271A (es)
CN (1) CN103906530B (es)
AP (1) AP2014007532A0 (es)
AR (1) AR087973A1 (es)
AU (1) AU2012318956A1 (es)
BR (1) BR112014007532A2 (es)
CA (1) CA2843520A1 (es)
CL (1) CL2014000801A1 (es)
CO (1) CO6910165A2 (es)
CR (1) CR20140142A (es)
DO (1) DOP2014000050A (es)
EA (1) EA201490521A1 (es)
EC (1) ECSP14013285A (es)
ES (1) ES2548214T3 (es)
IL (1) IL230754A0 (es)
IN (1) IN2014CN00782A (es)
MA (1) MA35458B1 (es)
MX (1) MX2014004159A (es)
PE (1) PE20142044A1 (es)
SG (1) SG11201401792UA (es)
TN (1) TN2014000096A1 (es)
TW (1) TWI461435B (es)
WO (1) WO2013052311A1 (es)
ZA (1) ZA201400882B (es)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20140012199A (ko) 2007-03-30 2014-01-29 암브룩스, 인코포레이티드 변형된 ｆｇｆ-21 폴리펩티드 및 그 용도
SG10201806648TA (en) 2011-07-01 2018-09-27 Ngm Biopharmaceuticals Inc Compositions, uses and methods for treatment of metabolic disorders and diseases
WO2013173158A1 (en) * 2012-05-15 2013-11-21 Eli Lilly And Company Therapeutic uses of fibroblast growth factor 21 proteins
EP2859014B1 (en) 2012-06-11 2017-04-26 Eli Lilly and Company Fibroblast growth factor 21 variants
TWI513705B (zh) 2012-06-11 2015-12-21 Lilly Co Eli 纖維母細胞生長因子２１蛋白質
US9963494B2 (en) 2012-11-28 2018-05-08 Ngm Biopharmaceuticals, Inc. Methods of using compositions comprising variants and fusions of FGF19 polypeptides for reducing glucose levels in a subject
US9290557B2 (en) 2012-11-28 2016-03-22 Ngm Biopharmaceuticals, Inc. Compositions comprising variants and fusions of FGF19 polypeptides
US9273107B2 (en) 2012-12-27 2016-03-01 Ngm Biopharmaceuticals, Inc. Uses and methods for modulating bile acid homeostasis and treatment of bile acid disorders and diseases
CN108888757A (zh) 2012-12-27 2018-11-27 恩格姆生物制药公司 用于调节胆汁酸体内稳态及治疗胆汁酸紊乱和疾病的方法
MX2016004822A (es) 2013-10-28 2016-08-17 Ngm Biopharmaceuticals Inc Modelos de cancer y metodos asociados.
MX2016009555A (es) 2014-01-24 2016-12-08 Ngm Biopharmaceuticals Inc Proteinas de union y metodos para utilizarlas.
WO2015138278A1 (en) * 2014-03-11 2015-09-17 Novartis Ag Methods of treating metabolic disorders associated with lipodystrophies and defects in insulin production or signaling
WO2015183890A2 (en) 2014-05-28 2015-12-03 Ngm Biopharmaceuticals, Inc. Methods and compositions for the treatment of metabolic disorders and diseases
AU2015277438B2 (en) 2014-06-16 2020-02-27 Ngm Biopharmaceuticals, Inc. Methods and uses for modulating bile acid homeostasis and treatment of bile acid disorders and diseases
UA123763C2 (uk) 2014-10-23 2021-06-02 Енджіем Байофармасьютикалз, Інк. Фармацевтична композиція для контролю або лікування захворювання або порушення, пов’язаного з fgf19
CA2965502A1 (en) 2014-10-24 2016-04-28 Bristol-Myers Squibb Company Modified fgf-21 polypeptides and uses thereof
US10434144B2 (en) 2014-11-07 2019-10-08 Ngm Biopharmaceuticals, Inc. Methods for treatment of bile acid-related disorders and prediction of clinical sensitivity to treatment of bile acid-related disorders
WO2017019957A2 (en) 2015-07-29 2017-02-02 Ngm Biopharmaceuticals, Inc. Binding proteins and methods of use thereof
AU2016353988B2 (en) 2015-11-09 2019-09-26 Ngm Biopharmaceuticals, Inc. Methods for treatment of bile acid-related disorders
TW201731867A (zh) * 2015-12-02 2017-09-16 賽諾菲公司 Ｆｇｆ２１變異體
WO2017220706A1 (en) * 2016-06-22 2017-12-28 Novo Nordisk A/S Pharmaceutical compositions of fgf21 derivatives and uses thereof
US11370841B2 (en) 2016-08-26 2022-06-28 Ngm Biopharmaceuticals, Inc. Methods of treating fibroblast growth factor 19-mediated cancers and tumors
CN106397607A (zh) * 2016-09-13 2017-02-15 河南师范大学 重组人成纤维细胞生长因子21融合蛋白及其在制备治疗代谢疾病药物中的应用
CN106220724B (zh) * 2016-09-13 2019-10-11 河南师范大学 人成纤维细胞生长因子21重组蛋白及其制备方法和应用
CN106432509B (zh) * 2016-09-13 2019-05-21 河南师范大学 一种治疗代谢疾病的重组人成纤维细胞生长因子21融合蛋白及其制备方法和应用
WO2018166461A1 (en) 2017-03-14 2018-09-20 Sunshine Lake Pharma Co., Ltd. Dual-target fusion proteins comprising the fc portion of an immunoglobulin
MX2020002206A (es) 2017-09-08 2020-07-20 Bristol Myers Squibb Co Factor de crecimiento de fibroblastos 21 (fgf-21) modificado para usarse en metodos para tratar la esteatohepatitis no alcoholica (nash).
US11679143B2 (en) 2018-02-08 2023-06-20 Sunshine Lake Pharma Co., Ltd. FGF21 variant, fusion protein and application thereof
WO2020010117A2 (en) 2018-07-03 2020-01-09 Bristol-Myers Squibb Company Fgf21 formulations
CN109836486B (zh) * 2019-01-30 2020-09-08 北京双因生物科技有限公司 成纤维生长因子21变体、其融合蛋白及其用途
CN111944055B (zh) 2019-05-16 2022-08-02 浙江道尔生物科技有限公司 一种治疗代谢疾病的融合蛋白
IL294534A (en) 2020-01-08 2022-09-01 Bristol Myers Squibb Co Formulations of fgf-21 conjugates
CN115322794A (zh) 2020-01-11 2022-11-11 北京质肽生物医药科技有限公司 Glp-1和fgf21的融合蛋白的缀合物
EP4192495A1 (en) 2020-08-07 2023-06-14 Bristol-Myers Squibb Company Fgf21 combined with ccr2/5 antagonists for the treatment of fibrosis
KR102495299B1 (ko) * 2020-11-03 2023-02-06 토드제약 주식회사 Fgf21의 열탄력성을 이용한 fgf21 생산 방법
US20240123031A1 (en) 2020-11-25 2024-04-18 Bristol-Myers Squibb Company Methods of treating liver diseases

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US7459540B1 (en) 1999-09-07 2008-12-02 Amgen Inc. Fibroblast growth factor-like polypeptides
WO2003011213A2 (en) 2001-07-30 2003-02-13 Eli Lilly And Company Method for treating diabetes and obesity
EA200601121A1 (ru) * 2003-12-10 2006-10-27 Эли Лилли Энд Компани Мутеины фактора роста фибробластов 21
BRPI0514790A (pt) 2004-09-02 2008-06-24 Lilly Co Eli muteìna de fgf-21 de humano, ou um seu peptìdeo biologicamente ativo, método para produzir a muteìna, composição farmacêutica, e, uso da muteìna de fgf-21 de humano
EP1789443A1 (en) 2004-09-02 2007-05-30 Eli Lilly And Company Muteins of fibroblast growth factor 21
KR20140012199A (ko) 2007-03-30 2014-01-29 암브룩스, 인코포레이티드 변형된 ｆｇｆ-21 폴리펩티드 및 그 용도
JOP20190083A1 (ar) * 2008-06-04 2017-06-16 Amgen Inc بولي ببتيدات اندماجية طافرة لـfgf21 واستخداماتها
WO2010065439A1 (en) * 2008-12-05 2010-06-10 Eli Lilly And Company Variants of fibroblast growth factor 21
WO2010129600A2 (en) 2009-05-05 2010-11-11 Amgen Inc. Fgf21 mutants and uses thereof
TWI560197B (en) 2009-05-05 2016-12-01 Amgen Inc Fgf21 mutants and uses thereof

Also Published As

Publication number Publication date
EP2763689B1 (en) 2015-08-12
KR20140059271A (ko) 2014-05-15
EA201490521A1 (ru) 2014-07-30
ZA201400882B (en) 2016-02-24
CN103906530B (zh) 2016-01-20
MA35458B1 (fr) 2014-09-01
MX2014004159A (es) 2015-02-12
AU2012318956A1 (en) 2014-02-06
EP2763689A1 (en) 2014-08-13
SG11201401792UA (en) 2014-08-28
WO2013052311A1 (en) 2013-04-11
PE20142044A1 (es) 2014-12-06
AP2014007532A0 (en) 2014-03-31
US8541369B2 (en) 2013-09-24
US20130324460A1 (en) 2013-12-05
JP6060167B2 (ja) 2017-01-11
TWI461435B (zh) 2014-11-21
CL2014000801A1 (es) 2014-09-12
DOP2014000050A (es) 2014-04-15
IL230754A0 (en) 2014-03-31
BR112014007532A2 (pt) 2017-04-04
ECSP14013285A (es) 2014-05-31
TW201326198A (zh) 2013-07-01
AR087973A1 (es) 2014-04-30
TN2014000096A1 (en) 2015-07-01
CO6910165A2 (es) 2014-03-31
US8883726B2 (en) 2014-11-11
IN2014CN00782A (es) 2015-04-03
CA2843520A1 (en) 2013-04-11
ES2548214T3 (es) 2015-10-14
US20130085098A1 (en) 2013-04-04
CN103906530A (zh) 2014-07-02
JP2014530220A (ja) 2014-11-17

Similar Documents

Publication Publication Date Title
CR20140142A (es) Variantes delfactor 21 del crecimiento de fibroblastos
ECSP14030742A (es) Proteínas del factor 21 de crecimiento del fibroblasto
MX2014015258A (es) Variantes del factor 21 de crecimiento de fibroblasto.
CL2013002414A1 (es) Compuestos derivados de azabencimidazol ciclico, activadores de la proteina cinasa activada por amp; composicion farmaceutica que los comprende; y su uso para el tratamiento o enfermedad tal como diabetes tipo 2, hiperglicemia, sindrome metabolico, obesidad, hipercolesterolemia e hipertension.
CL2012003211A1 (es) Compuestos derivados de lactamas sustituidas con piperidinilo, moduladores de gpr119; proceso para preparar los compuestos; composicion farmaceutica que comprende a los compuestos; y uso de los compuestos en la preparacion de medicamentos para el tratamiento o prevencion de diabetes tipo 2, obesidad y condiciones relacionadas
CR20130234A (es) Métodos de tratamiento de trastornos asociados con el fgf21
DOP2014000115A (es) Uso de 4-fenil-piridinas sustituidas para la fabricación de medicamentos útiles en el tratamiento de enfermedades relacionadas con el receptor de nk1
UY34859A (es) Análogos peptídicos de la exendina 4.
CR20150149A (es) Proteínas de fusión para el tratamiento de un síndrome metabólico
DOP2013000192A (es) Compuestos y composiciones como inhibidores de la trk
CR20110509A (es) Composicion farmaceutica
CL2011002942A1 (es) Compuestos derivados de 2,4-diamino-pirimidina, agonistas de receptor tipo toll-7 (tlr7); composicion farmaceutica; y su uso para el tratamiento del cancer.
CR20110255A (es) Nuevos compuestos 578
BR112015000578A2 (pt) moduladores da via do complemento e usos dos mesmos
UY32778A (es) Terapia de combinación para el tratamiento de la diabetes
ECSP13012573A (es) 6-amino-nicotinamidas sustituidas como moduladores de KCNQ2/3
ECSP16078782A (es) Compuestos de isoindolinona como moduladores de gpr119 para el tratamiento de diabetes, obesidad, dislipidemia y trastornos relacionados
BR112013029256A8 (pt) combinação farmacêutica para uso no tratamento de pacientes com diabetes tipo 2
BR112014031091A2 (pt) Derivados de piperidina para agonista de gpr119
UY32167A (es) Nuevos derivados de 2-amidotiadiazol
UY32734A (es) Compuestos agonistas del receptor esfingosina 1-fosfato
UY35668A (es) Derivados de azabencimidazol como agonistas de ampk y composiciones farmacéuticas que los contienen
ECSP13012453A (es) 2-oxi-quinolina-3-carboxamidas sustituidas como moduladores KCNQ2/3
UY33529A (es) Composiciones farmacéuticas para el tratamiento de enfermedades respiratorias e inflamatorias?
ECSP13012460A (es) 2-oxo- y 2-tioxo-dihidroquinolina-3-carboxamidas sustituidos como moduladores KCNQ2/3